The move reflects Alpha’s commitment to building on its collaborative growth equity model in global tech hubs like Israel.

NEW YORK, Sept. 4, 2025 — Alpha Partners, a leading growth equity firm that invests in growth rounds led by the world’s best investors, today announced the appointment of Gal Gitter as a Partner. Gitter will be based in Tel Aviv and will lead Alpha’s efforts to bring its collaborative growth equity model to Israel.

The appointment reflects Alpha’s view that Israel remains one of the world’s most important technology ecosystems. The firm’s model—designed to partner with early-stage venture funds rather than compete against them—helps early investors double down on their best-performing companies at the growth stage by supplying capital through pro-rata rights.

This approach has powered Alpha’s investments in globally recognized businesses such as Coupang, Careem, Chainguard, Apptronik, Socure, and Baseten.

“Today, Alpha sees about half of the U.S.’s growth rounds per year and, with our VC partners, has the ability to invest in about a quarter of these deals,” said Steve Brotman, Managing Partner of Alpha Partners. “Our pioneering VC partnership model enables us to invest in what we believe to be the most promising companies globally at the growth stage, typically investing alongside the top VCs in the world. Historically, Israeli-founded companies account for 1 in 6 U.S. tech unicorns. As such, we are excited to formally launch our model in Israel, as we believe the country will continue generating some of the world’s most important tech companies.”

Gitter was formerly Head of Ibex’s Israel Growth Fund and a leader within McKinsey’s Corporate Development Group. His experience spans investment and operational roles across Israeli startups and global investors.

“Alpha is one of the few firms purpose-built to collaborate with other funds rather than compete with them,” said Gitter. “That ethos resonates in Israel, where early investors play a central role in helping companies launch but often can’t continue participating as those companies scale. By bringing Alpha’s model to Israel, we can empower early stage investors to continue their partnership with their portfolios’ top performers at the growth stages.”

Alpha has already completed multiple Israeli founded investments leveraging its partnership model, including in cybersecurity companies Semperis and Zero Networks, underground mapping leader Exodigo and AI/Healthtech player Vi Labs. The fund’s Israel operations are co-led by Steve Brotman and Gal Gitter, with Charlie Federman serving as a Venture Partner and Lior Avisar serving as a Venture Investor.

About Alpha Partners
Alpha Partners is a $400 million AUM growth equity firm that invests alongside early-stage venture capital firms in their highest-performing companies. Over the past 12 years, the firm has pioneered the model of partnering with early investors to leverage their pro-rata rights, providing the capital needed to maintain its VC partner’s ownership and support continued involvement in their portfolio companies. Alpha has relationships with nearly half of all U.S. and Israeli headquartered VCs, over 1,000 venture capital firms that are invested in nearly 4 in 5 technology companies. Alpha has invested in more than 30 growth-stage companies worldwide. The portfolio companies identified and described herein do not represent all of the portfolio companies purchased, sold or recommended for funds advised by Alpha Partners. AUM indicated is as of September 2025. Certain information contained herein may constitute “forward-looking statements and are based on information presently available to Alpha. Due to various risks and uncertainties, actual events or results may differ materially from those reflected or contemplated in such forward-looking statements. This press release is not a solicitation of an offer to purchase securities and may not be relied upon in connection with the purchase or sale of any security. Learn more at alphapartners.com

SOURCE Alpha Partners

PITTSBURGH, Sept. 4, 2025 — Pointsville, a pioneering platform for digital asset infrastructure and loyalty, today announced the successful completion of its Series A funding round led by Valor Capital Group, with participation from an exceptional group of global investors and industry leaders. Backers include Tether, Itaú Unibanco’s founding family, Nubank’s co-founder, Temasek-backed Superscrypt, SNZ, Credit Saison, K2 Integrity, Citrino, and Dynamo‘s partners.

The round unites a uniquely powerful coalition: the world’s leading stablecoin operator, Latin America’s largest banks, Asia’s leading financial services firms, and globally recognized risk, intelligence, and financial firms. Together, they bring unparalleled reach and expertise to accelerate Pointsville’s mission of bridging traditional assets with next-generation digital asset infrastructure. With the tokenized real-world asset (RWA) market projected to exceed $10 trillion by 2030, we are leading this transformation by setting the standard for how traditional assets move into digital markets.

The steady maturation of the digital asset ecosystem has fueled unprecedented demand for the tokenization of real-world assets (RWA). Existing infrastructure has fallen short, fragmenting assets, data, and liquidity across traditional and onchain finance. Pointsville fills this gap with purpose-built tokenization infrastructure, shaped by the founders’ firsthand experience bridging institutional finance and digital assets.

As part of the financing, Bruno Batavia, Principal and Director of Emerging Tech at Valor Capital Group, has joined Pointsville’s Board of Directors. Batavia previously served more than a decade at Brazil’s Central Bank, where he played a key role in launching the Digital Real (DREX) initiative and led the Tokenization Working Group, shaping how central banks implement tokenized asset infrastructure globally.

Gabor Gurbacs, Founder and CEO of Pointsville: “Pointsville is built for the next era of market infrastructure where real-world assets converge with digital networks in an open, borderless global marketplace. This round brings us extraordinary partners whose reach and expertise will accelerate that vision and transformation worldwide.”

Ricardo Villela Marino, Vice Chairman of Itaú: “Ricardo Villela Marino, Vice Chairman of Itaú Unibanco, commented:

“While I serve as Vice Chairman of Itaú, I want to emphasize that my support for Pointsville is a personal investment, independent from the bank. I believe the company is addressing one of the most important frontiers in global finance: building the infrastructure that will allow real-world assets to move seamlessly into digital markets. Pointsville has the vision and capability to shape how this sector evolves, and I am excited to support their journey as they help set the standards for the next era of market infrastructure.”

Paolo Ardoino, CEO of Tether: “Tokenization is rapidly emerging as one of the most practical and impactful drivers of real-world asset adoption. Hadron by Tether is proud to support this transformation, collaborating with Pointsville’s experienced team to deliver the scale and usability required to integrate real-world assets and loyalty programs into the digital economy.”

Bruno Batavia, Valor Capital Group: “Pointsville represents the kind of breakthrough platform we want to support—one with the potential to transform financial infrastructure across regions and asset classes through tokenization as we move toward truly global capital markets on blockchain rails. We are excited to partner with Gabor and his team to scale this opportunity.”

The Series A closing coincides with the rollout and expansion of major Pointsville-powered initiatives, including serving as the core technology provider for Hadron by Tether and powering new loyalty and experiences, such as the Fanatics FanCash program, and advancing projects with leading institutions and governments. Proceeds will accelerate product development, expand partnerships, and scale infrastructure to meet global demand.

Learn more at pointsville.com.

Media Contact (Media Only):

Alexandre Lores
Email: [email protected] 

SOURCE Pointsville

Honey secures backing from Pelion Ventures, Streamlined, 8-Bit Capital, and Burst Capital to expand its All-in-One AI Back Office for Healthcare.

MOUNTAIN VIEW, Calif., Sept. 4, 2025 — Administrative overload and staff turnover continue to strain healthcare organizations—slowing care and squeezing margins. Honey Health, an All-in-One AI Back Office platform, deploys secure AI agent teams that complete complex, end-to-end administrative work directly inside the EHR—automating the workflows that burden nearly every organization across primary care and specialty settings.

Today, Honey announced a $7.8 million seed round led by Pelion Ventures, with participation from Streamlined, Burst Capital, and 8-Bit Capital. Launched in December, Honey is already working with over 100 organizations and has helped them save millions in administrative costs.

Healthcare organizations face unprecedented operational strain, with rising workloads and 33–40% annual turnover in non-clinical staff. Traditional point solutions solve only fragments of the problem, require constant oversight, and rarely integrate well—leaving care teams overburdened and margins under pressure.

Honey’s AI Back Office embeds specialized AI agents directly into provider systems, including most EHRs. These agents work together like skilled staff to securely complete complex workflows without manual handoffs or separate interfaces.

     “Healthcare organizations are stuck between two broken models: point solutions that only solve narrow tasks and a constant struggle to hire and retain back-     office staff,” said Matt Faustman, Co-Founder and CEO of Honey Health. “Honey flips that script. We let organizations deploy full AI agent teams that work      autonomously in the background—completing complex back-office workflows inside the EHR, without manual prompting. It’s real leverage to scale care with      fewer staff and stronger margins.”

With more capabilities on the way, Honey’s AI agents currently automate the high-volume administrative workflows shared across most specialties and primary care settings, including:

• Data Fetching — Fetches data from external sources (labs, devices, and other systems)
• Note Prep — Prepares visit-ready patient notes and charts
• Orders & Refills — Handles post-visit orders and refills 24/7
• Fax Triage — Sorts, routes, and files faxes while extracting key details
• Prior Authorizations — Manages the full authorization process

Honey stands out with its proprietary Loop framework and Hive protocol, which allow its AI agents to onboard quickly to most EHRs, understand each organization’s workflows, and complete entire jobs that typically require multiple point solutions—without a co-pilot interface. The work just gets done.

Customers report $50,000–$66,000 in annual profit gains per provider, driven by reduced reliance on offshore labor and fewer backfills for high-turnover roles.

     “Using Honey Health is like magic—our back-office work just gets done inside our EHR as if a staff member had completed it,” said Dr. Kashif Latif, co-owner      of AM Endocrinology in Memphis, one of the largest endocrinology practices in the southeastern United States and a Honey Health customer.

Honey was founded by Matt Faustman and Xiao Zhang, former LinkedIn AI, product, and engineering leaders. The two met while working on AI initiatives at LinkedIn after Faustman sold his previous company to the platform. Both founders have personal experiences with chronic disease and care delays due to administrative bottlenecks—Faustman, for example, was diagnosed with Type 1 Diabetes 10 years ago.

     “Healthcare providers are desperate to find ways to automate their back office, and Honey Health is by far the best product to do it,” said Tyler Hogge, Partner      at Pelion Ventures. “They’ve built a solution that handles several of the highest-value tasks needed to operate more efficiently—and doctors and operations      teams love it.”

The funding will help expand Honey’s platform with additional capabilities, enabling its fast-growing customer base to automate even more of the back office and further reduce administrative costs.

For specialty and multi-specialty providers, hospitals, and health systems looking to reduce back-office burdens and improve margins, visit www.honeyhealth.ai.

Press Kit: Click Here

Media Contact: [email protected]  

SOURCE Honey Health

CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity;
CTA to be filed in 2H 2025

MONTREAL, Sept. 4, 2025 — Congruence, a computationally-driven biotechnology company building a unique pipeline of pharmacological correctors for diseases of protein misfolding, including MC4R-deficient (MC4R-d) genetic obesity, GBA1-driven Parkinson’s disease and Alpha-1 antitrypsin (A1AT) deficiency, announced today the closing of a US $32 million financing round.

The round included participation from all existing investors including: Amplitude Ventures, FSTQ, Lumira, Investissement Quebec, BDC Capital’s Thrive Venture Fund, OrbiMed, Driehaus, Silver Arc, and Alexandria.

“This financing enables us to generate the first clinical proof of concept data with our corrector for MC4R-d driven obesity, a serious and debilitating condition without current treatment options,” commented Dr. Clarissa Desjardins, CEO of Congruence. “We will also advance our programs in GBA-1 Parkinson’s Disease and Alpha-1 Antitrypsin Deficiency toward Development Candidate nomination this year.”

Congruence plans to start a Phase 1 trial of CGX-926 in healthy volunteers, including a Phase 1b efficacy cohort in MC4R-d patients, in early 2026. Congruence will also advance its programs targeting Parkinson’s Disease and A1AT-deficiency into late preclinical testing.

“Congruence is building a transformative pipeline of drugs it has discovered leveraging its powerful computational engine, Revenir™. The team has demonstrated scientific rigor and capital efficiency in advancing these important medicines into late preclinical testing,” commented Daniel Hétu, M.D., MBA, Managing Director at Lumira Ventures. “We are proud to continue to support Congruence as it advances its lead program CGX-926 into clinical testing and inches closer towards its mission of treating diseases of high unmet medical need.”

The Company also continues to advance its R&D collaborations, including a multi-target deal in oncology with Ono Pharmaceuticals and another collaboration on a difficult to drug metabolic target with an undisclosed pharmaceutical company.

“Too many patients with devastating genetic conditions have been left without effective treatments. Congruence’s small-molecule corrector approach offers new hope for people affected by MC4R-driven obesity, GBA Parkinson’s, A1AT deficiency and cancer.  We are honored to support their mission through our investment in Congruence,” added Nancy Harrison, Venture Partner at Amplitude Ventures.

About Revenir™ Drug Discovery Platform

Revenir™, Congruence’s proprietary computational drug discovery platform, captures the dynamic biophysical changes caused by mutations in proteins, offering unique insights into protein defects and their correction. By examining surface features and a spectrum of biophysical descriptors across an ensemble of protein conformers, Revenir™ predicts small molecule induced correction of the underlying pathogenic defect in proteins.

About Congruence Therapeutics

Congruence is a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Our proprietary scalable platform, Revenir™, captures the biophysical features of proteins across their conformational ensembles, in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter. Congruence has leveraged its proprietary discovery engine to launch a pipeline of wholly owned drugs directed to high-value, genetically validated, difficult-to-drug targets spanning a variety of indications including genetic obesity, GBA Parkinson’s Disease, and α1-Antitrypsin Deficiency. Congruence is further deploying its discovery platform to support two multi-target research collaborations with large pharmaceutical companies focused on the discovery of small molecule correctors for the treatment of solid tumors and metabolic diseases.

For more information, please visit www.congruencetx.com.

Company Contact
Charles Grubsztajn
Chief Operating Officer
[email protected]

Media Contact
Amy Conrad
Juniper Point
[email protected] 
858-366-3243

SOURCE Congruence Therapeutics

This follows their $30 million seed round last year, bringing the total raised to $65M. The company will use the new funds to advance its AI capabilities

TEL AVIV, Israel, Sept. 4, 2025 — Sola Security, the Cybersecurity AI assistant, announced today it has raised a $35 million Series A round led by existing investor S32 and joined by M12, Microsoft’s Venture Fund, and New Era Capital Partners. All existing investors, including venture capitalist Mike Moritz, S Capital, and Glilot Capital Partners joined the round as well. Sola Security brings the AI revolution to cybersecurity, redefining how security challenges are approached and solved, squeezing weeks and days of effort into minutes.

Founded in 2024 by cybersecurity veterans Guy Flechter (former CEO & Co-Founder of Cider Security, acquired by Palo Alto Networks) and Ron Peled (former Global CISO of LivePerson and strategic security consultant to startups), Sola was born from their frustration with the stagnation in Cybersecurity innovation. They set out to build a solution which would make cybersecurity faster and easier to tackle, without compromising the quality and safety these solutions provide. Reflecting Gartner’s expectation that AI assistants will evolve into context-aware copilots for security teams, Sola is advancing technology designed to reduce repetitive workload and enhance decision support, all backed by baked-in security logic and reasoning.

In the six months since emerging from stealth, Sola Security has garnered more than 2,000 users who created over 1,000 custom security apps with Sola’s generative AI, spanning from identity and access management to cloud security, posture and configuration management, compliance, and more.

“Cybersecurity is entering its AI moment, and we intend to lead it,” said Guy Flechter, CEO & Co-Founder of Sola Security. “We’re building the go-to platform for creating security solutions, with Sola AI turning ideas into instant, customizable defenses without the complexity, cost, or vendor locking that has held teams back for decades. Just as design, payments, and collaboration were reimagined by the likes of Canva, Stripe, and Figma, we’re redefining how cybersecurity challenges are solved. Our industry needs to move faster, and to do what needs to be done so solutions are simple, lightweight, and tailored to specific needs. We’re thrilled to be leading the charge.”

“Sola is redefining what’s possible in cybersecurity,” said Wesley Tillu, Partner at S32. “By combining deep industry experience with a bold vision for AI-driven innovation, the team is building a platform that will transform how security challenges are solved for years to come. We’re proud to lead this round and support Sola as they set a new course for the future of the industry.”

“Sola is transforming cybersecurity as we know it and ushering it into the age of AI,” said Todd Graham, Managing Partner at M12. “In just a year, the team has already shown the vision and execution to make that transformation real. Sola is exactly the kind of company we love working with: a founding team with an extraordinary vision, a product that proves itself quickly, and a team that sees opportunity in every challenge.”

“AI is reshaping industries at an unprecedented pace, and cybersecurity is no exception,” said Ziv Conen, Partner at New Era Capital Partners. “Sola is bringing that transformation to security teams, democratizing cybersecurity and empowering practitioners to seize the AI promise faster, and better than ever. What impressed us most is the combination of speed, discipline, and deep expertise the Sola team brings, which combined with their bold vision, sets them apart and positions them to define a new era in cybersecurity.”

About Sola Security

Sola Security is a Cybersecurity AI assistant empowering teams to take control of their security solutions quickly and easily, with minimal resource investment. Sola AI enables organizations of all sizes and individuals to prompt their stack and create security solutions in minutes. Sola ensures security teams can create the security solutions they need, as well as better understand and maximize the effectiveness of their existing security stack. For more information, visit sola.security.

Sola Security Media Contact

Danielle Blumenstyk Peterman
[email protected]

Headline Media Contact

Mushkie Meyer
[email protected]
IL:+972 53 612 1118
US:+1 914 336 4035
UK:+44 203 769 4034

SOURCE Sola Security

Transformation Capital leads round to scale AI-native compliance infrastructure trusted by top Life Science and Fortune 500 companies

CAMBRIDGE, Mass. and VIENNA, Sept. 4, 2025 — Ketryx, the AI-powered compliance platform helping life sciences companies ship safer products faster, today announced a $39 million Series B led by Transformation Capital, with participation from existing investors including Lightspeed Venture Partners, MIT’s E14 Fund, Ubiquity Ventures, and 53 Stations. This latest round brings the company’s total funding to over $55 million, and Vinay Shah, Partner and Founding Team Member at Transformation Capital, will join Ketryx’s board.

Ketryx is solving one of the most difficult challenges in the life sciences: the need to accelerate product innovation without compromising safety or compliance. This challenge is more urgent than ever with teams racing to incorporate AI into regulated workflows and products.

“I’ve spent the last decade at the intersection of AI and life sciences, watching it evolve from an emerging tool to a critical application for patients,” said Erez Kaminski, CEO and founder of Ketryx. “It’s now time to accelerate adoption and ensure AI is safe, reliable, and ready for regulated environments.”

Life sciences teams are struggling to balance rigorous compliance requirements amid the rapidly accelerating pace of innovation. While cloud-based tools and rapidly evolving LLMs are transforming what’s possible, these regulated teams are still operating on infrastructure not designed for this velocity of change.

Ketryx is an AI-native compliance platform built to meet this challenge. It automates validation, traceability, and regulatory workflows—including FDA/EU MDR-ready documentation—across the product development lifecycle to help teams release safer products faster. Customers report up to a 90% reduction in documentation time and over 10x faster release cycles.

“In Medtech, long-term success depends on balancing innovation with the uncompromising demands of safety and compliance,” said Bill Hawkins, former CEO of Medtronic and new Ketryx investor. “This balance has historically been hard to achieve. Ketryx has built the infrastructure that allows both to advance together. Their ability to deliver this level of rigor at true enterprise scale is why I’m proud to support them as they shape the future of regulated software.”

The company’s platform is built for the enterprise and already used by three of the top five global medtech companies, several Fortune 500 organizations, and AI-powered companies such as DeepHealth, Heartflow, and Aignostics. With adoption accelerating, Ketryx is emerging as the key AI infrastructure layer for product development in regulated industries.

“Medtech teams are leading the way in applying artificial intelligence to improve patient outcomes, creating products that meet the highest safety and regulatory standards,” said Vinay Shah, Partner and Founding Team Member at Transformation Capital. “In our diligence, Fortune 500 giants and fast-growing innovators consistently praised Ketryx for proving that compliance can accelerate, rather than slow, technological progress. We believe Ketryx is defining the future of regulated infrastructure across industries and are proud to back them in their next stage of growth.”

Kaminski continued, “Having Transformation Capital, the pre-eminent digital health VC & growth equity firm, as our lead partner, gives us more than just capital. They understand exactly what it takes to build and scale healthcare technology companies. With their backing and industry connections, we’re continuing our global expansion, accelerating our product roadmap, and hiring rapidly in both Boston and Austria.”

With real-time traceability and documentation, Ketryx brings zero-lag compliance to the heart of product development, empowering teams to release more products, more safely, and faster than ever before.

About Ketryx
Ketryx transforms the product lifecycle of life science teams to deliver safer products, faster. Trusted by three of the world’s top five medical device manufacturers, its AI-powered compliance platform overlays existing tools to automate documentation, create traceability, and accelerate release cycles—without disrupting existing workflows. Ketryx AI Agents cut manual work by 90 percent and close compliance gaps, elevating speed and quality across the entire product lifecycle. For more information, visit www.ketryx.com.

SOURCE Ketryx

Platform simplifies the deep research process for AI and data science teams.

CHICAGO, Sept. 4, 2025 — Nimblemind, an AI company built to help healthcare institutions and researchers unlock the full value of their data, announced the launch of NimbleLabs. This latest product is a lightweight AI platform designed to make clinical data enrichment accessible to data science teams, researchers and students. With an intuitive upload-and-enrich workflow, NimbleLabs allows users to convert raw clinical data into structured, analysis-ready outputs – enabling insights in hours instead of months. 

NimbleLabs uses AI to enrich multimodal data in preparation for analysis and modeling. The platform is purpose-built for healthcare institutions and innovators looking to accelerate research, improve data workflows, and experiment with AI-ready datasets without needing to build infrastructure from scratch. NimbleLabs supports commonly used data types in healthcare, such as: unstructured clinical notes, images, videos, streaming wearable data, patient surveys, and more. 

“Healthcare needs AI that is clinically relevant, scalable, and trustworthy. NimbleLabs transforms raw clinical data into AI-ready datasets in hours, not months, empowering researchers and healthcare systems to accelerate discovery and build solutions in areas of medicine that have long been overlooked. This is how we bring AI from the lab to the bedside.”

• Brian Khan, MD, MBA, Medical Director of Digital Health and Well-Being, Internal Medicine Physician, UChicago Medicine AdventHealth

The platform builds on Nimblemind’s mission to help providers and researchers enrich multimodal clinical data with structure, traceability, and context. NimbleLabs harnesses a proprietary AI enrichment engine that provides automated preprocessing, intent detection, and specialty-specific enrichment tuned to real-world healthcare needs.

“We built NimbleLabs to unlock the full potential of healthcare data. By making it faster and easier to prepare datasets for AI, we’re helping providers and researchers spend less time on manual prep and more time delivering new discoveries, better care, and measurable impact.”

• Pi Zonooz, CEO and Co-founder of Nimblemind.ai

The launch follows Nimblemind.ai’s $2.5M seed round earlier this year, led by Bread & Butter Ventures with participation from Great Oaks VC, SpringTime Ventures, Techstars, and others. Nimblemind’s products are used by healthcare organizations across the US and Asia in several specialties, including: palliative care, gastroenterology, pathology, geriatrics, and public health. 

NimbleLabs is available starting today at https://nimblelabs.ai/signup. For a limited time, users can create a free account and immediately begin transforming datasets.

About The Company
Nimblemind.ai helps healthcare organizations curate and enrich multimodal clinical data. Their platform is actively analyzing and transforming health data for customers across the U.S. and Asia. What used to take weeks of manual annotation is now completed in under a week—delivering 10x faster data labeling and dataset prep, and enabling rapid deployment of predictive models and research tools.

The founding team brings deep technical and clinical expertise: their Chief AI Officer has a PhD in Healthcare AI from Yale and previously led data science at NYC Health + Hospitals; their CEO helped build and launch over 40 products at AWS.

Early pilots highlight:

• Powers high performance models (>90% accuracy) in predicting patient outcomes, giving providers time to intervene and avoid relapse or ER utilization.
• 80% reduction in healthcare data scientist’s time spent on preprocessing, profiling, and harmonizing raw datasets, giving staff more time to focus on developing and validating models.
• 20% reduction in operational costs by streamlining workflows traditionally requiring several hours of expert labor – now completed within minutes.

SOURCE Nimblemind.ai

Global investment firm strengthens early-stage presence across the US and Canada to back the next generation of international champions with a first close of $25m

MONTREAL and TORONTO , Sept. 4, 2025 — White Star Capital, the global multi-stage technology investment firm, has announced a first close of $25m for its new North American Seed Fund anchored by the Fonds de solidarité FTQ. The strategy is designed to back high-potential startups from pre-seed through seed stages across the region.

The fund will support early-stage founders building globally scalable solutions across the US and Canada. At a time when the world is being revolutionised by AI and new technologies, White Star Capital is stepping forward with fresh capital, operational support, and a long-term commitment to founders with a bold vision from day one.

“As a Series A and B investor deeply embedded in the New York, Toronto, and Montreal tech ecosystems for the past decade, my colleagues and I have always dreaded having to pass on exceptional founders that were “too early” for us,” said Sanjay Zimmermann, General Partner. “With the strategic support of Fonds de solidarité FTQ, we are thrilled to be in a position to provide North American entrepreneurs with an unfair advantage, even earlier in their journey.”

“Over the past ten years, the Fonds de solidarité FTQ has made direct and indirect venture capital investments totalling $2.7 billion. With this new seed fund from White Star Capital, we are continuing our commitment to emerging companies shaping the economy of the future – an effort reflected as well in our support for Ax.c, the new initiative for Quebec’s tech startups and innovative entrepreneurs,” said Dany Pelletier, Executive Vice-President of Private Equity and Impact Investing at the Fonds de solidarité FTQ.

Other Limited Partners joining the first close include Capital régional et coopératif Desjardins (CRCD), Fonds québécois d’amorçage Teralys financed by La Caisse, and TD Innovation Partners (TDIP), a division of The Toronto-Dominion Bank.

The North American Seed Fund expands on White Star Capital’s decade-long track record of early-stage investing, having already backed more than 100 companies worldwide and generated top-quartile returns across multiple vintages. The new initiative will be co-managed by Sanjay Zimmermann, a long-time investor at the firm, based in Toronto, and Catherine Ouellet-Dupuis, based in Montreal, a veteran operator with experience as Chief Strategy and Corporate Development at Workleap, an IT and HR tech company that scaled to $100m+ in ARR.

“I’m excited to be joining White Star Capital to build a Seed Fund that gives local early-stage companies the backing they need to grow into global champions,” said Catherine Ouellet-Dupuis, General Partner. “Having been through the challenges of scaling a business internationally, I know how valuable it is to have the right people in your corner. With White Star Capital’s global platform, network, and deep market insights, I’m looking forward to working side-by-side with founders and joining a team that’s known for rolling up its sleeves to help them succeed.”

White Star Capital’s seed-stage strategy combines local conviction with global connectivity. Founders in the portfolio gain access to a network of experienced venture partners, advisors, and go-to-market experts across the firm’s hubs in New York, Toronto, Montreal, Austin, Miami, London, Paris, Zurich, the UAE, and Singapore. The fund will write lead investments of $0.5m to $2m, with follow-on capital reserved to support breakout companies through Series A and beyond.

As part of the final close, White Star Capital plans to announce a new General Partner for its new North America Seed Fund based in New York. With the first close now completed, White Star Capital is actively seeking founders across North America building recurring revenue businesses aligned with its macro themes, and encourages bold, ambitious teams to get in touch.

About White Star Capital

White Star Capital is a global technology investment firm partnering with exceptional entrepreneurs building international businesses at scale. Operating across North America, Europe, and Asia, the firm combines deep local relationships with a global platform to help portfolio companies expand internationally and become category leaders.

The firm currently has three active funds in operation: an Early Growth Fund that invests globally in Series A/B companies, a Digital Asset Fund focused on crypto and blockchain-enabled startups, and now a North American Seed Fund.

About the Fonds de solidarité FTQ

The Fonds de solidarité FTQ is a source of pride in Québec, fulfilling its mission through a unique business model created more than 40 years ago. Since then, the Fonds has rallied Québec into action thanks to the retirement savings of over 808,000 shareholders.

With net assets of $21.9 billion as of May 31, 2025, the Fonds supports directly and indirectly thousands of companies through venture and development capital investments based on the belief that the impact of its investments is created as much by financial as societal returns. For more information, visit fondsftq.com or our company page on LinkedIn.

SOURCE White Star Capital

NEW YORK, Sept. 3, 2025 — Utila emerges as the go-to operating system for stablecoins as institutional demand for digital asset infrastructure explodes

Utila has closed a $22 million Series A extension round just six months after announcing its Series A, bringing its total A round to $40 million and nearly tripling the company’s valuation. The extension, led by Red Dot Capital Partners with participation from Nyca, Wing VC, DCG, Cerca Partners, FunFair Ventures and SilverCircle, brings the total funding to more than $51 million and reflects the explosive demand for Utila’s digital asset operations platform as organizations worldwide adopt stablecoins for payments, treasury management and operational workflows.

The rapid-fire extension round materialized without Utila actively seeking capital, as the company received multiple inbound investment offers driven by hypergrowth across all key metrics. With almost all of its original Series A funding still in the bank, the company chose to extend the round to accelerate market capture in the exploding digital asset infrastructure sector.

Since its Series A announcement in March, Utila has seen unprecedented growth driven by mainstream adoption of stablecoins across financial services and more than doubled its customer base. The company now processes over $15 billion in monthly volume and has secured more than $90 billion in total transactions. With hundreds of global institutional customers, Utila has rapidly established itself as the operating system for stablecoins, providing the secure, scalable infrastructure that enterprises need to build, manage and scale digital asset operations.

The Stablecoin Infrastructure Imperative

“We’re witnessing a fundamental shift in how organizations handle value transfer, with stablecoins at the center of this transformation,” said Bentzi Rabi, co-founder and CEO of Utila. “Six months ago, we positioned ourselves for the next wave of digital asset adoption. Today, that wave has arrived, and Utila has become the essential infrastructure layer for any organization working with stablecoins – from global payment providers to stablecoin issuers to financial institutions building next-generation treasury and trading operations.”

The rapid extension round underscores the massive market opportunity as stablecoin adoption accelerates across industries. The first half of 2025 pushed stablecoins deeper into the financial mainstream, with aggregate supply climbing to $252 billion and monthly settlement volumes rising 43% to $1.39 trillion. Payment providers, neobanks and financial institutions are increasingly integrating stablecoins into their core operations, creating unprecedented demand for enterprise-grade infrastructure that can handle the complexity, security and compliance requirements of institutional digital asset operations.

“Utila represents exactly the kind of category-defining company we look to back — one that sits at the intersection of a massive technological shift and clear enterprise demand,” said Atad Peled, Partner at Red Dot Capital Partners. “The stablecoin market is exploding, and organizations need enterprise-grade tools to operate safely and efficiently. Utila’s rapid growth and strong customer traction show they’ve built the platform the market truly needs.”

The Complete Digital Asset Operations Platform

Utila’s platform handles four core functions that address the full spectrum of digital asset operations:

• Stablecoin Operations – Complete infrastructure for stablecoin issuers, payment providers and enterprises integrating stablecoin workflows into their business operations
• Treasury Operations – Secure, policy-driven treasury management for digital assets with granular controls and compliance frameworks
• Trading Operations – Institutional-grade trading infrastructure across centralized exchanges and DeFi protocols
• Business Continuity – Seamless wallet environment mirroring capabilities for mission-critical operations

Built by cryptography and cybersecurity experts, Utila combines military-grade security with the operational flexibility that modern institutions require. The platform features secure enterprise-grade MPC wallets, granular policy controls, robust developer APIs, multi-chain support, payments and tokenization engine, comprehensive integrations to AML providers, exchanges, DeFi, and banking rails, and insurance coverage providing additional protection for institutional assets.

“Most institutional wallet providers are still solving yesterday’s problems: trading connectivity and exchange integrations,” explained Rabi. “The infrastructure requirements for operational use cases are fundamentally different from traditional crypto trading. Organizations need platforms that can handle high-volume transactions, complex compliance workflows and enterprise-grade security – all while maintaining the speed and flexibility that digital assets enable. We provide that complete solution, which is why we are the fastest growing, all-in-one wallet platform in the market today.”

Proven Enterprise Platform with Global Reach

The extension funding will accelerate Utila’s global expansion and product development as the company scales to meet surging demand for digital asset infrastructure. Beyond strengthening its presence in North America and Europe, the company plans to expand aggressively in emerging markets where stablecoins play pivotal roles in financial infrastructure – particularly LATAM, APAC and Africa – as regulatory frameworks in these regions continue to mature.

Utila’s client roster spans the full digital asset ecosystem: payment service providers integrating USDC rails, neobanks building stablecoin products, institutional trading firms accessing DeFi liquidity, and stablecoin issuers managing minting operations and more. This breadth contrasts with point solutions in the market targeting specific use cases.

Utila’s rapid growth trajectory positions the company at the forefront of the institutional digital asset adoption wave. As stablecoins become the backbone of next-generation financial infrastructure, Utila provides the essential operating system that enables organizations to participate securely, efficiently and at scale.

About Utila

Founded in 2022 by Bentzi Rabi (CEO) and Sam Eiderman (CTO), Utila is the secure, all-in-one digital asset operations platform for institutions. Utila enables organizations to securely manage and build on digital assets. Trusted by 200+ global institutions, Utila processes more than $15 billion in monthly volume and has secured over $90 billion in transactions.

Utila has raised more than $50 million in total funding from leading investors including Nyca Partners, Red Dot Capital Partners, Wing VC, NFX, Framework Ventures and DCG, along with prominent angel investors including Balaji Srinivasan, Charlie Songhurst and more.

Users can learn more at https://utila.io/

Media Contact

Montner Tech PR
Deb Montner
[email protected]

Contact

Surya Deepan Elango
Utila
[email protected] 

Photo – https://mma.prnewswire.com/media/2764077/Utila.jpg

SOURCE Utila